RESULTS OF RADIATION THERAPY IN 19 DOGS WITH CUTANEOUS MAST CELL TUMOR AND REGIONAL LYMPH NODE METASTASIS
Article first published online: 19 MAY 2005
Veterinary Radiology & Ultrasound
Volume 43, Issue 4, pages 392–395, July 2002
How to Cite
Chaffin, K. and Thrall, D. E. (2002), RESULTS OF RADIATION THERAPY IN 19 DOGS WITH CUTANEOUS MAST CELL TUMOR AND REGIONAL LYMPH NODE METASTASIS. Veterinary Radiology & Ultrasound, 43: 392–395. doi: 10.1111/j.1740-8261.2002.tb01023.x
- Issue published online: 19 MAY 2005
- Article first published online: 19 MAY 2005
- Received August 8, 2000; accepted for publication October 10, 2001.
- mast cell tumor;
- megavoltage radiation
The records of 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis (WHO Stage 2) were reviewed to determine the efficacy of radiation therapy in this population. Dogs with grade I (n= 1), grade II (n= 16), and grade III (n= 2) cutaneous mast cell tumor were included in this study. All dogs were treated with a combination of pre-irradiation surgical cytoreduction of the primary tumor, irradiation of the primary tumor and regional lymph node, and oral prednisone. Total radiation dose to the primary tumor and regional lymph node ranged from 48 to 57 Gray (Gy). The medial iliac and hypogastric lymph nodes were irradiated prophylactically in 11 dogs with primary tumor of the pelvic limb and positive ipsilateral popliteal lymph node. Total radiation dose to these lymph nodes ranged from 48 to 57 Gy. For all radiation fields, dose per fraction was 3 Gy, and therapy was administered on a Monday through Friday schedule. Acute and late radiation side effects observed in this study were considered acceptable. The median disease-free survival was 1,240 days (95% confidence interval 256 to 2,391 days). The disease-free survival in dogs with stage 2 mast cell tumor suggests that the combination of surgery, irradiation, and prednisone for the primary tumor along with irradiation of the positive lymph node is effective.